knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 19:25:47 - browse：873

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Paxlovid should be available without a positive Covid test

WSS

Address the ethical violations that led to 'Three Identical Strangers'

Why the quest to eradicate polio has stumbled

Data show record exodus of life scientists from academia

PBMs drew scrutiny in House hearing — and so did pharma

Medicare drug price negotiation program allowed for now

'A game

knowledge

knowledge

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA panel to weigh safety of artificial wombs for preterm births

Moonlake's readout produced a cash windfall. Risks remain

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Virginia high school admissions case could be legal follow

Menendez indictment could see pharma lose a key ally

BioMarin wins approval for gene therapy to treat hemophilia A

How the messy conversation about Dolly changed bioethics

Supreme Court strikes down use of affirmative action

People with substance use disorder deserve online privacy

focus

People with substance use disorder deserve online privacy

David Liu startup to focus on CRISPR delivery

Intercept Pharmaceuticals sells itself for less than $1 billion

After a drawn out lobbying fight, ARPA

Kaiser Permanente unions announce official strike date

Information blocking fines are now fair game in health care

entertainment

focus

focus

hotspot